International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Lilly Press Release Graphic

Eli Lilly and Company announced on August 8 the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The new formula, approved by the United States Food and Drug Administration (FDA) in May 2022, contains the same active ingredient as the original formulation. Still, patients experience significantly less pain at the injection site. Existing Taltz patients will not need a new prescription and should not experience a gap in their therapy. The new formula is expected to be available, to new and existing patients, across the United States by the end of the month. The citrate-free formulation was also approved by the European Medicines Agency in December 2021, with several markets launching now and more anticipated in the coming months. IPC’s councilor, April Armstrong, MD, MPH, was quoted in the press release saying: “Today is an exciting milestone for the nearly 30 million people around the world who live with the challenging symptoms of these autoimmune diseases that affect the skin and joints. In my six years of prescribing Taltz, I have seen firsthand the significant impact Taltz has had for patients across multiple indications. The availability of Taltz as a citrate-free formulation represents an important advance in patient care that will allow more patients to experience less injection-site pain.”

Employees advance our mission with big ideas, unique perspectives, and the dedication to bring relief to millions around the world.

2 thoughts on “Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

  1. David Robertson says:

    Very impressed with the new formula. No pain at all with this latest injection.

  2. Jake Robertson says:

    Any news if this will be administered in Australia?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Recent Posts

New IPC Guidelines on Generalized Pustular Psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.